Bottom line: Kaiser is one of the hardest insurers for Wegovy coverage
It was generally well-tolerated, and most patients experienced improvements in their condition [3]
These trials monitor weight changes alongside metabolic indicators, cardiovascular markers, and organ function over extended periods
Scholar Rock The drug developer is testing apitegromab, an experimental therapy that targets the myostatin protein, in combination with Eli Lilly's weight-loss treatment Zepbound
CZ CELLxGENE Discover: a single-cell data platform for scalable exploration, analysis and modeling of aggregated data
A cardiovascular risk-reduction indication was subsequently added following the SELECT trial, reported by Lincoff and colleagues in 2023 [7]